Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 23 Oct 2017

Yang W J, Gao Y B, Qiu T, Wang Y G, He J

Abstract excerpt

Objective: To investigate the efficacy of tyrosine kinase inhibitor (TKI) treatment on non-small cell lung cancer (NSCLC) patients with postoperative recurrence who harbored uncommon EGFR mutations, and discuss the relationship between TKI treatment and prognosis. Methods: A total of 39 relapsed NSCLC patients after surgery with EGFR uncommon mutations who were detected at Cancer Hospital, Chinese Academy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Mutagenesis, Insertional

Share to Neoplasm Recurrence, Local

Share to Point Mutation

Share to Postoperative Period

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29061015
DOI: 10.3760/cma.j.issn.0253-3766.2017.10.003

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].PMID 29061015Read ↗

[Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Clinical features and outcomes of unresectable locally advanced non-small cell lung cancer with uncommon EGFR Mutations: A retrospective multi-center Chinese studySemantic proximity Read ↗

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.Semantic proximity Read ↗

[Efficacy of first generation EGFR-TKIs and chemotherapy as first-line therapy in advanced lung adenocarcinoma patients with uncommon EGFR mutations].Semantic proximity Read ↗

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.Semantic proximity Read ↗

Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.Semantic proximity Read ↗

Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?Semantic proximity Read ↗

Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.Semantic proximity Read ↗

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.Semantic proximity Read ↗

Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical ResectionSemantic proximity Read ↗

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.